

MaterniT[®]

21 PLUS

Insights into your
baby's health as early
as nine weeks into your
pregnancy



The pioneering NIPT—safe, accurate, and
ordered more than 900,000 times to date

Pioneering science, personalized service



Understand your cost options

Visit our website for your cost estimate and personalized payment options and the opportunity to learn about our *Moms Helping Moms of Tomorrow* initiative. www.integratedgenetics.com/transparency



Convenient blood draws

Getting your blood drawn is easier than ever. As a LabCorp company, we have a nationwide network of patient service centers, allowing for convenient access to sample collection. Visit www.LabCorp.com to find your nearest location.



Genetic counseling

Patients with a positive test result may be offered counseling, and Sequenom and Integrated Genetics offer the largest national commercial network of genetic counselors to help inform and support patients.



Every Mom Pledge

We believe every mom should have access to the best possible care. That's why we work directly with you to make sure our testing services are accessible and out-of-pocket costs are transparent.



A noninvasive
blood test

With a blood draw from you as early as nine weeks into your pregnancy, the MaterniT® 21 PLUS test can screen for certain chromosomal abnormalities that could affect your baby's health and development, providing you with more information earlier in your pregnancy.

Did you know that information on your baby's health can be found in your own bloodstream?

The MaterniT 21 PLUS test analyzes genetic information that enters your bloodstream from the placenta. It screens for certain chromosomal abnormalities that could affect your baby's health and development—such as trisomy 21 (Down syndrome) and sex chromosome aneuploidies (SCAs, abnormal numbers of X or Y chromosomes)—and can also detect if you're having a boy or a girl.

The MaterniT 21 PLUS test detects the following chromosomal abnormalities:

TRISOMIES	SCAS*
Trisomy 21 (Down syndrome)	45,X (Turner syndrome)
Trisomy 18 (Edwards syndrome)	47,XXY (Klinefelter syndrome)
Trisomy 13 (Patau syndrome)	47,XXX (Triple X syndrome)
	47,XYY (XYY syndrome)

There are many ways to get this information, including methods such as serum screens and diagnostic procedures such as amniocentesis.

* Reported as an additional finding. Talk to your doctor about your options.



As a noninvasive prenatal test, MaterniT 21 PLUS is different from both. It has higher detection rates than serum screening¹ (determined to be 97.9% positive predictive value for trisomy 21 in a high-risk cohort²), and requires only a blood draw from the mother; amniocentesis requires withdrawing fluid from around the developing baby.

Most women who get the MaterniT 21 PLUS will screen negative for chromosomal abnormalities and may not require further testing.

However, any patient with a positive test result may be offered genetic counseling and/or diagnostic testing for confirmation of test results.

Accurate, easy-to-understand results

MaterniT 21 PLUS is the pioneering noninvasive prenatal test.

Since its introduction in 2011, the test has been ordered more than 900,000 times and validated in clinical studies.

And unlike some similar tests, MaterniT 21 PLUS delivers answers in terms you can easily understand, with clear positive or negative results for well known chromosomal abnormalities, such as trisomy 21 (Down syndrome), typically returned within five days.

Also, if you're carrying twins, MaterniT 21 PLUS can detect common chromosomal abnormalities in multiple gestation pregnancies.



Toll-free
(within the US)

877.821.7266

www.integratedgenetics.com

askSQNMCS@labcorp.com



Watch a short video to learn about the test:

integratedgenetics.com/videos

Sequenom Laboratories
3595 John Hopkins Court
San Diego, CA 92121



Sequenom Center for Molecular Medicine, LLC d/b/a Sequenom Laboratories, a wholly owned subsidiary of Sequenom, Inc., is a CAP-accredited and Clinical Laboratory Improvement Amendment (CLIA)-certified molecular diagnostics laboratory dedicated to improving patient outcomes by offering revolutionary laboratory-developed tests for a variety of prenatal conditions. Sequenom, Inc. is a wholly owned subsidiary of Laboratory Corporation of America Holdings. Sequenom®, Sequenom Laboratories™, and MaterniT® are trademarks of Sequenom, Inc. This brochure is provided by Integrated Genetics as an educational service for healthcare providers and their patients.

Note: This material is provided for general information purposes only. It is not intended as a substitute for medical advice and/or consultation with a physician or technical expert.

REFERENCES

1. Practice Bulletin No. 163 Summary. (2016). *Obstetrics & Gynecology*, 127(5), 979-981.
2. Porreco RP, Garite TJ, Maurel K et al. Noninvasive prenatal screening for fetal trisomies 21, 18, 13 and the common sex chromosome aneuploidies from maternal blood using massively parallel genomic sequencing of DNA. *Am J Obstet Gynecol* 2014;211:365.e1-12.



LabCorp Specialty Testing Group